ProCE Banner Activity

Where Might Investigational Long-Acting 2-Drug Combinations of ARVs With Novel Mechanisms of Action Fit Into the Future HIV Treatment Landscape?

Clinical Thought
Thoughts on how investigational, long-acting 2-drug regimens involving drugs with novel mechanisms of action may expand treatment options not only for treatment-experienced patients, but also for ART-naive patients in key populations with specific needs.

Released: November 30, 2021

Expiration: November 29, 2022

No longer available for credit.

Share

Faculty

Karine Lacombe

Karine Lacombe, MD, PhD

Professor
UMR-S1136
Sorbonne University
Professor
Head, Infectious Diseases Department
St Antoine Hospital, AP-HP
Paris, France

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Educational grant provided by

Merck Sharp & Dohme Corp.

ViiV Healthcare

Faculty Disclosure

Primary Author

Karine Lacombe, MD, PhD

Professor
UMR-S1136
Sorbonne University
Professor
Head, Infectious Diseases Department
St Antoine Hospital, AP-HP
Paris, France

Karine Lacombe, MD, PhD, has disclosed that she has received consulting fees from AbbVie, Chiesi, Gilead Sciences, and Janssen.